- Home
- SF vs EXEL Comparison
SF vs EXEL Comparison
Compare SF & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- EXEL
- Stock Information
- Founded
- SF 1890
- EXEL 1994
- Country
- SF United States
- EXEL United States
- Employees
- SF N/A
- EXEL N/A
- Industry
- SF Investment Bankers/Brokers/Service
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SF Finance
- EXEL Health Care
- Exchange
- SF Nasdaq
- EXEL Nasdaq
- Market Cap
- SF 9.8B
- EXEL 10.4B
- IPO Year
- SF N/A
- EXEL 2000
- Fundamental
- Price
- SF $113.68
- EXEL $39.01
- Analyst Decision
- SF Buy
- EXEL Buy
- Analyst Count
- SF 8
- EXEL 21
- Target Price
- SF $114.88
- EXEL $43.65
- AVG Volume (30 Days)
- SF 620.2K
- EXEL 2.3M
- Earning Date
- SF 10-22-2025
- EXEL 10-28-2025
- Dividend Yield
- SF 1.60%
- EXEL N/A
- EPS Growth
- SF 9.88
- EXEL 81.76
- EPS
- SF 5.17
- EXEL 2.08
- Revenue
- SF $5,091,577,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- SF $10.70
- EXEL $9.24
- Revenue Next Year
- SF $12.22
- EXEL $13.04
- P/E Ratio
- SF $22.30
- EXEL $18.72
- Revenue Growth
- SF 11.86
- EXEL 10.73
- 52 Week Low
- SF $73.27
- EXEL $25.17
- 52 Week High
- SF $120.64
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- SF 51.02
- EXEL 53.48
- Support Level
- SF $111.63
- EXEL $36.78
- Resistance Level
- SF $116.21
- EXEL $39.27
- Average True Range (ATR)
- SF 2.13
- EXEL 0.94
- MACD
- SF -0.24
- EXEL 0.31
- Stochastic Oscillator
- SF 36.71
- EXEL 91.45
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.